Andrew Cooper
Stock Analyst at Raymond James
(2.40)
# 2,442
Out of 5,180 analysts
143
Total ratings
42.11%
Success rate
-0.53%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AZTA Azenta | Maintains: Outperform | $35 → $45 | $20.25 | +122.22% | 3 | Nov 25, 2025 | |
| ITGR Integer Holdings | Reiterates: Outperform | $143 → $95 | $85.16 | +11.55% | 4 | Oct 24, 2025 | |
| HOLX Hologic | Downgrades: Market Perform | n/a | $75.55 | - | 13 | Oct 22, 2025 | |
| AVTR Avantor | Maintains: Outperform | $14 → $16 | $7.59 | +110.80% | 16 | Oct 16, 2025 | |
| HAE Haemonetics | Downgrades: Outperform | $105 → $78 | $54.93 | +42.00% | 10 | Aug 11, 2025 | |
| GH Guardant Health | Maintains: Outperform | $59 → $61 | $86.20 | -29.23% | 4 | Jul 31, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $120 → $115 | $84.78 | +35.65% | 9 | Jul 29, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $525 → $535 | $480.05 | +11.45% | 7 | Jul 24, 2025 | |
| MYGN Myriad Genetics | Reiterates: Outperform | $19 → $10 | $4.36 | +129.36% | 5 | May 7, 2025 | |
| FLGT Fulgent Genetics | Reiterates: Outperform | $24 → $25 | $15.63 | +59.95% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $186.76 | - | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $183.89 | - | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $16.43 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $186.84 | -54.51% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $15.26 | +398.03% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $4.30 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $7.20 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $30.44 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.92 | - | 5 | Sep 22, 2021 |
Azenta
Nov 25, 2025
Maintains: Outperform
Price Target: $35 → $45
Current: $20.25
Upside: +122.22%
Integer Holdings
Oct 24, 2025
Reiterates: Outperform
Price Target: $143 → $95
Current: $85.16
Upside: +11.55%
Hologic
Oct 22, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $75.55
Upside: -
Avantor
Oct 16, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $7.59
Upside: +110.80%
Haemonetics
Aug 11, 2025
Downgrades: Outperform
Price Target: $105 → $78
Current: $54.93
Upside: +42.00%
Guardant Health
Jul 31, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $86.20
Upside: -29.23%
Revvity
Jul 29, 2025
Reiterates: Outperform
Price Target: $120 → $115
Current: $84.78
Upside: +35.65%
Thermo Fisher Scientific
Jul 24, 2025
Reiterates: Outperform
Price Target: $525 → $535
Current: $480.05
Upside: +11.45%
Myriad Genetics
May 7, 2025
Reiterates: Outperform
Price Target: $19 → $10
Current: $4.36
Upside: +129.36%
Fulgent Genetics
May 5, 2025
Reiterates: Outperform
Price Target: $24 → $25
Current: $15.63
Upside: +59.95%
Mar 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $186.76
Upside: -
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $183.89
Upside: -
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $16.43
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $186.84
Upside: -54.51%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $15.26
Upside: +398.03%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $4.30
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $7.20
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $30.44
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $2.92
Upside: -